Biomet Plans No Major Restructuring Following Private Equity Buy-Out
This article was originally published in The Gray Sheet
Executive Summary
Biomet's new CEO Jeffrey Binder said in an interview that he plans to maintain the company's current structure for the foreseeable future
You may also be interested in...
Investment Advisors Argue Private Equity Offer For Biomet Is Too Low
An investor advisor group is urging Biomet shareholders to reject a proposed $10.9 billion private equity buyout because it represents too small a premium over the orthopedic company's value
Investment Advisors Argue Private Equity Offer For Biomet Is Too Low
An investor advisor group is urging Biomet shareholders to reject a proposed $10.9 billion private equity buyout because it represents too small a premium over the orthopedic company's value
Biomet Accepts $10.9 Bil. Private Equity Buyout To Stay Independent
Orthopedic device makers Smith & Nephew and Biomet ended discussions on a possible merger after Biomet announced plans to become a private, independent company by the end of October